{
  "relevance": {
    "rules": [
      {
        "rule_id": "relevance_rule_1",
        "rule_text": "All abstracts that coincide with the disease area of interest (IgAN) or mention any client keyword related to IgA nephropathy.",
        "processing_type": "keyword_filtering",
        "include_logic": {
          "any_of": [
            {
              "categories": [
                "Disease of Interest",
                "Clinical Trial",
                "Company",
                "Disease",
                "Endpoints",
                "Other",
                "Treatment",
                "Treatment Class"
              ],
              "field": "keywords",
              "values": [
                "PROTECT",
                "ALIGN",
                "ORIGIN 3",
                "RUBY-3",
                "NCT05799287",
                "VISONARY",
                "APPLAUSE",
                "Novartis",
                "Roche",
                "Travere",
                "Otsuka",
                "Vera",
                "Alpine",
                "Vertex",
                "Remegen",
                "IgA Nephropathy",
                "Proteinuria; OR UPCR",
                "UACR",
                "eGFR",
                "KDIGO",
                "Remission",
                "Disease modification",
                "IgA-IgG immune complexes",
                "Subgroup",
                "immunosuppression",
                "non-immunosuppression",
                "pathogenic Mechanisms",
                "B cell depletion +/- activation +/- targeting",
                "MEST-C",
                "treatment options",
                "Clinical Trial Endpoints",
                "Biomarkers",
                "Complement proteins +/- C3 +/- C4",
                "Standard of care",
                "targeted-release formulation budesonide",
                "Telitacicept",
                "Sparsentan",
                "Iptacopan",
                "Atrasentan",
                "Zigakibart",
                "Povetacicept",
                "Sibeprenlimab",
                "Atacicept",
                "Methylprednisone +/- methylprednisolone",
                "BAFF +/- APRIL; OR APRIL alone; OR BAFF/April; OR Blys/April; OR APRIL/BLyS",
                "AT1/EDNRA antagonist? +/- ERA +/- endothelian receptor antagonist",
                "Complement Factor B inhibitor +/- alternative pathway +/- complement inhibition? +/- complement system inhibitors",
                "ENDR Antagonist",
                "Systemic +/- steroid +/- glucocorticoid +/- corticosteroid",
                "SGLT2 +/- SGLT2 inhibition",
                "optimized supportive care +/- ACE/ARB +/- RASi +/- RAASi",
                "Gd-IgA OR IgA1 OR Gd-IgA1 OR Galactose deficient",
                "Chinook",
                "Immune Complex",
                "budesonide",
                "prednisone",
                "TRF budesonide",
                "Veloxis",
                "Asahi Kasei",
                "Tarpeyo",
                "Kinpeygo"
              ]
            }
          ]
        },
        "exclude_logic": ""
      },
      {
        "rule_id": "relevance_rule_2",
        "rule_text": "All abstracts describing Calliditas sponsored studies.",
        "processing_type": "keyword_filtering",
        "include_logic": {
          "any_of": [
            {
              "categories": ["Company"],
              "field": "keywords",
              "values": ["Calliditas"]
            }
          ]
        },
        "exclude_logic": ""
      }
    ]
  },
  "priorities": {
    "Very High": {
      "rules": [
        {
          "rule_id": "very_high_sub_rule_1",
          "rule_text": "Abstracts assigned as Very High priority by the Calliditas team.",
          "processing_type": "none",
          "include_logic": {
            "any_of": [{ "categories": [], "field": "keywords", "values": [] }]
          },
          "exclude_logic": ""
        }
      ]
    },
    "High": {
      "rules": [
        {
          "rule_id": "high_sub_rule_1",
          "rule_text": "All relevant abstracts that include any of the following: Phase 2/3 data (including meta-analyses), real-world data (including patient reported outcomes, retrospective analyses and registry data).",
          "processing_type": "context_filtering",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Phase 2/3 data",
                  "Meta-analyses",
                  "Real-world data",
                  "Patient reported outcomes",
                  "Retrospective analyses",
                  "Registry data"
                ],
                "field": "context",
                "values": [
                  "Phase 2 data",
                  "Phase 3 data",
                  "meta-analysis",
                  "real-world data",
                  "patient reported outcomes",
                  "retrospective analysis",
                  "registry data"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Medium": {
      "rules": [
        {
          "rule_id": "medium_sub_rule_1",
          "rule_text": "All relevant abstracts that include any of the following: Phase 1 data, general HEOR studies, prognostic studies, preclinical studies, other general studies.",
          "processing_type": "context_filtering",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Phase 1 data",
                  "HEOR studies",
                  "Prognostic studies",
                  "Preclinical studies",
                  "General studies"
                ],
                "field": "context",
                "values": [
                  "Phase 1 data",
                  "HEOR",
                  "prognostic study",
                  "preclinical study",
                  "general study"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Low": {
      "rules": [
        {
          "rule_id": "low_sub_rule_1",
          "rule_text": "All relevant abstracts that only have mention of an indication of interest and do not include any other data.",
          "processing_type": "keyword_filtering",
          "include_logic": {
            "any_of": [
              {
                "categories": ["Disease of Interest", "Disease"],
                "field": "keywords",
                "values": ["IgA Nephropathy"]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    }
  }
}
